Get started
Author

Kosta Tsaparikos

Observed name: Kostantinos Tsaparikos
Observed institution: Pfizer (United States)
OpenAlex ID: A5020243201
Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design
2010 · Ping Wei, Marlena Walls, et al. · Molecular Cancer Therapeutics · 196
SAR and chemistry of Aurora kinase inhibitors: Discovery of PF-3814735, an oral clinical candidate
2008 · Samit K. Bhattacharya, Donn G. Wishka, et al. · Cancer Research · 5
Supplementary Figures 1-4 from Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design
2023 · Ping Wei, Marlena Walls, et al.
Supplementary Table 1 from Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design
2023 · Ping Wei, Marlena Walls, et al.
Supplementary Table 2 from Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design
2023 · Ping Wei, Marlena Walls, et al.
Data from Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design
2023 · Ping Wei, Marlena Walls, et al.
Data from Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design
2023 · Ping Wei, Marlena Walls, et al.
Supplementary Table 3 from Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design
2023 · Ping Wei, Marlena Walls, et al.
Supplementary Table 3 from Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design
2023 · Ping Wei, Marlena Walls, et al.
PDF
MEDI 340-Design, synthesis and evaluation of a potent class of spiroindoline pyrrolopyrimidines targeting Akt as anticancer agents
2007 · Goss S. Kauffman, Joel T. Arcari, et al. · Abstracts of papers - American Chemical Society
Works count: 10
Citation count: 201
H-index: 2
I10-index: 1
Year
Topic
Type